AC Immune Ltd (NASDAQ:ACIU) Rating Lowered to Hold at Zacks Investment Research
Zacks Investment Research downgraded shares of AC Immune Ltd (NASDAQ:ACIU) from a buy rating to a hold rating in a research report sent to investors on Wednesday, July 12th.
According to Zacks, “AC Immune SA is a biopharmaceutical company. It develops, discover and design novel, proprietary medicines for prevention, diagnosis and treatment of neurodegenerative diseases. The Company’s pipeline includes Crenezumab, ACI-24, Anti-Tau antibody, Morphomer Tau, Tau-PET imaging agent, Morphomer Abeta and Morphomer alpha-syn which are in clinical trial. AC Immune SA is based in Lausanne, Switzerland. “
Separately, Credit Suisse Group set a $18.00 price target on AC Immune and gave the company a buy rating in a report on Wednesday, May 31st.
AC Immune (NASDAQ:ACIU) remained flat at $6.70 during mid-day trading on Wednesday. The company had a trading volume of 17,658 shares. AC Immune has a one year low of $6.66 and a one year high of $19.97. The company’s market capitalization is $381.38 million. The company’s 50 day moving average is $8.53 and its 200-day moving average is $10.19.
AC Immune (NASDAQ:ACIU) last announced its quarterly earnings results on Thursday, May 11th. The company reported ($0.17) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.17). The business had revenue of $1.99 million during the quarter, compared to analyst estimates of $3.43 million. AC Immune had a negative return on equity of 27.54% and a negative net margin of 471.34%. Equities research analysts predict that AC Immune will post ($0.57) earnings per share for the current year.
TRADEMARK VIOLATION WARNING: “AC Immune Ltd (NASDAQ:ACIU) Rating Lowered to Hold at Zacks Investment Research” was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another domain, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The correct version of this article can be read at https://www.thecerbatgem.com/2017/08/07/ac-immune-sa-nasdaqaciu-cut-to-hold-at-zacks-investment-research-updated-updated-updated.html.
Large investors have recently bought and sold shares of the company. Victory Capital Management Inc. raised its stake in AC Immune by 78.4% in the first quarter. Victory Capital Management Inc. now owns 26,757 shares of the company’s stock valued at $277,000 after buying an additional 11,757 shares during the period. Cohen Lawrence B bought a new stake in AC Immune during the second quarter valued at $297,000. Monashee Investment Management LLC raised its stake in AC Immune by 74.7% in the first quarter. Monashee Investment Management LLC now owns 30,000 shares of the company’s stock valued at $311,000 after buying an additional 12,832 shares during the period. GSA Capital Partners LLP bought a new stake in AC Immune during the fourth quarter valued at $457,000. Finally, FMR LLC raised its stake in AC Immune by 13.4% in the fourth quarter. FMR LLC now owns 3,637,402 shares of the company’s stock valued at $46,344,000 after buying an additional 428,815 shares during the period. Hedge funds and other institutional investors own 18.47% of the company’s stock.
About AC Immune
AC Immune Ltd is a Switzerland-based company engaged in the medical biotechnology sector. It develops treatments for Alzheimer’s and other neurodegenerative diseases, such as Down syndrome, glaucoma and Parkinson’s, and focuses on producing therapeutic and diagnostic product candidates, using SupraAntigen and Morphomer technology platforms.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for AC Immune Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune Ltd and related stocks with our FREE daily email newsletter.